Keep God Weird

SAN ANTONIO -- Thousands of people took to the streets of San Antonio on Saturday for the 11th yearly Susan G. Komen Race For The Cure.

The event, which drew an estimated 28,000 people, raised $1 million for breast malignant neoplastic disease research, organisers said.

Among those running play in the event was six-year breast malignant neoplastic disease subsister Nelda Juarez.

"It's such an inspiration to see so many people out here supporting us," Ciudad Ciudad Juarez said. "It really intends a lot."

"We necessitate to maintain doing this until we happen a cure," said Linda McCullers, a race participant.

The race is the biggest fundraiser for breast malignant neoplastic disease research in San Antonio.

WHAT: Pink Ribbon House Tour

WHERE: 5316 Longmont

WHEN: Thursdays-Sundays, April 3-20. Hours are 10 a.m.-3 p.m. Thursdays-Fridays, Ten a.m.-5 p.m. Saturdays and noon-5 p.m. Sundays.

COST: $15 at the door.

INFORMATION: 713-540-2529.

In 2003, the Pink Ribbon House undertaking was created to convey attending to breast malignant neoplastic disease research at Baylor College of Medicine. Since then, the design, ornament and circuit of three show window places have helped 100s of military volunteers and patrons raise almost $2 million for the Lester and Sue Ian Smith Breast Center, which focuses on prevention, diagnosing and treatment of the disease.

This year's rock and stucco, Tuscan-inspired home by Covington Builders is modeled after an Italian villa. Nearly 6,300 foursquare feet of life space include a maestro sleeping room suite downstairs, three en suite bedrooms, two further half-baths and a household room that stretches two stories. A Sub-Zero icebox and Wolf contraptions impart modern seal to an Old-World-style kitchen. Custom completes include plaster walls by Leslie Upton Sinclair of Segreto Finishes.

The house, which names at nearly $3 million, is being marketed by Martha Nat Turner Properties.

358 of 413 drug patent of invention applications for the disease in Republic Of India are from top multinationals.

The recent legal changes by reversal suffered by transnational major league Novartis and Roche over patents of invention for malignant neoplastic disease medical specialty could be the tip of a immense iceberg.

A city-based policy research grouping have got establish that transnational drug houses have filed over 350 patent of invention applications for drugs used in malignant neoplastic disease treatment.

An analysis of drug company patent of invention of invention of invention applications pending with the patent business office by the group, which did not wish to be identified, have set the figure of malignant neoplastic disease drug patent applications at 413. Of these, 358 came from top multinationals like Novartis, Aventis, Bristol Myers Squibb, Pfizer, Boehringer, Roche and Abbot.

The haste for patents of invention on malignant neoplastic disease medical specialty can be explained by the possible of the Rs 1,200 crore Indian market.

With nearly 2.5 million patients, malignant neoplastic disease is one of the 10 leading causes of decease in India. Data beginnings from the National Cancer Register Program show that over 700,000 new lawsuits and 300,000 deceases happen annually owed to cancer.

However, not all 413 applications will go through muster with the patent of invention of invention office, a patent expert warned. Republic Of India makes not give patents of invention on drugs patented elsewhere before 1995.

The patent of invention of invention expert said only two drugs in the listing of applicantions were granted patent in the United States after 1995. Most applications, people involved in the research said, are for derived functions or minor alterations of medical specialties that are not eligible for patents.

"Our analysis shows that most of these applications make not measure up for patents of invention in India. Therefore, the patent of invention testers necessitate to be very careful while scrutinising them," the research worker who takes the survey said.

The concerns of the research workers addition more significance in the background of the Old Delhi High Court's interim order allowing Cipla to marketplace its anti-cancer drug, Erlontib, though Roche was granted a patent of invention on it. Tarceva is the first and only malignant neoplastic disease medical specialty to acquire a merchandise patent of invention of invention (the patent that denies the entry of low-cost copycat versions of the medicine) in India.

The other malignant neoplastic disease medicine, Glivec, from Novartis, was denied a patent of invention of invention in the state because the patent business office felt that the medical specialty was an improvement of a known matter and hence non-patentable.

Novartis have appealed against the patent of invention denial to the Intellectual Place Appellate Board (IPAB). The high-profile patent of invention warfare have been considered a diagnostic test lawsuit in pre-grant resistance of patent applications.

Imagine dedicating your life to lovingness for people with malignant neoplastic disease only to happen out that this time, you are the 1 with the disease.

For 27 years, Arlene Spires, the head executive director of the Ulster Cancer Foundation, have devoted her clip and energy to helping others with the illness.

Then, just five hebdomads ago she was diagnosed with breast cancer.

"It was interesting as I have got spoken to so many 100s of people over the course of study of my career," Arlene said.

"I've spoken to them; I've understood what it's been like for them.

"It was phantasmagoric in a sense. I thought; 'Is the operating surgeon talking about person else?'"

Arlene started her calling as a nurse hoping to educate women about breast cancer, a hard undertaking in itself, at the clip it was a disease no-one spoke about.

Now, after working in every facet of the charity's outreach and prima the arrangement as its head executive, she confronts a rough reality.

"I immediately thought of my family, my hubby first and foremost, who was even more than apprehensive than I'd ever known him in our life together.

"My sisters, because I have got two ses and indeed my brother, so I thought about what it was going to be like to state them.

'Difficult time'

"So many people have got said the most hard portion of that journeying was telling their closest friends.

"I have got many friends over Northern Eire and abroad but my household were the cardinal people when I got the diagnosis."

It is a complete function reversal for Arlene to travel from carer to receiver.

The issue is the same, but now the focusing is on her.

"I said to the oncologist: 'Everything you've said to me is nil new, I understand all that, I cognize because I've gone through it so many modern times with others.'

"I have got the further penetration of what it is like for a household member to travel through breast cancer, my sister some old age ago, was diagnosed with breast malignant neoplastic disease and I think that helped me because she have been a truly inspiring individual in my life.

"She is now doing extremely well."

At this point, it is now up to Arlene to take the advice and attention she have given to so many and focusing on getting well.

"I am extremely positive about the result of my breast cancer.

"I'm clearly not looking forward to the adjacent six calendar months during which clip I will have got a series of chemotherapy treatments and radiation therapy treatment at the end of that.

"However, it is good news and my end is to be portion of that good news story."

In recent years, the result for breast malignant neoplastic disease endures in Northern Eire have improved and Arlene states this is what assists her expression to the future.

"At the end of the process, my breast malignant neoplastic disease should be treated successfully.

"I will retrieve from the treatment and move forward to life a normal life again, if anyone can ever dwell a normal life again after having a diagnosing of cancer, however that's my end and that's what I be after to do."

NEW
YORK: A chemical compound establish in soys looks to forestall spreading of human prostate
cancer, according to the latest
research. Researchers state that
the measure of the chemical, an antioxidant known as genistein, used in the
experiments was what a human would normally eat in a soyabean-rich
diet. Investigators from
Northwestern University establish that Genistein was establish to diminish metastasis of
prostate malignant neoplastic disease to the lungs by 96 percent, compared with mice that did not eat
the chemical compound in their chow, Science
Daily reported. "These impressive
results give us trust that genistein might demo some consequence in preventing the
spread of prostate gland malignant neoplastic disease in patients," said the study's senior investigator,
Raymond C. Bergan of the Northwestern
University. "Certain chemicals
have good personal effects and now we have got got all the pre-clinical studies we necessitate to
suggest genistein might be a very promising chemo-preventive drug," said
Bergan. Bergan and his team
have previously demonstrated in prostate gland gland malignant neoplastic disease cell civilizations that genistein
inhibits withdrawal of malignant neoplastic disease cells from a primary prostate tumour and represses
cell invasion. It makes this by
blocking activation of p38 map kinases, molecules which modulate nerve pathways that
activate proteins that loosen malignant neoplastic disease cells from their tight clasp within a
tumour, pushing them to migrate. Investigators fed genistein to
several groupings of mice before implanting them with an aggressive word form of
prostate cancer. The amount of genistein in the blood of the animate beings was
comparable to human blood concentrations after ingestion of soybean foods, Bergan
said. The research workers found
that while genistein didn't cut down the size of tumors that developed within the
prostate, it stopped lung metastasis almost completely. They repeated the
experiment and establish the same
result. These determinations have
been published in March issue of Cancer
Research

It's not the most pleasant topic. But knowing how to guard against colorectal malignant neoplastic disease could salvage your life.

In fact, according to the Prevent Cancer Foundation, colorectal malignant neoplastic disease is nearly 90 percentage preventable.

The No. One measure you can take to take down your hazard is to follow guidelines for showing for the disease, states Dr. Brian Sipe, a gastroenterologist with Northside Gastroenterology who is affiliated with St. Vincent Hospital.

Other preventative measurements are:

1Eat less meat: Reducing fat from meat in your diet looks to have got got got an consequence on colon cancer, Sipe says.

2Watch what you imbibe -- and smoke: Beer drinkers have been shown to have a higher charge per unit of colon cancer, but that may be because people who down a few brewages are likely to be in scenes where there's cigarette smoke, Sipe says. Smoke duplicates your hazard of colon cancer.

3Know the symptoms: In the early stages, there may be no symptoms. But later on, according to the Prevent Cancer Foundation, symptoms can include rectal bleeding, alteration in intestine habits, narrower stools, tummy uncomfortableness such as as cramps, diarrhoea or constipation, unexplained weight loss, changeless fatigue and vomiting.

4Get screened: The best bar is regular screening. A colonoscopy is recommended for all people aged than 50, and once every five to 10 old age thereafter, Sipe says.

Recently, the American Cancer Society added two options to traditional colonoscopy: Less invasive "virtual" colonoscopy and a stool diagnostic test that expressions for deoxyribonucleic acid cast from tumors.

But a recent survey also showed that level lesions on the colon wall are more than likely to be debatable than polyps. Thus, surveys that approved the option methods may necessitate to be redone, Sipe says.

-- Shari River Rudavsky

The figure of aged Americans getting
diagnostic tests rose to 61 percentage in 2006, from 54 percent
four old age earlier, U.S. wellness functionaries reported.

People age 50 and aged were less likely to acquire screened if
they were poor, less educated, achromatic or lacking wellness insurance,
according to the and Prevention
in Atlanta.

Colorectal tumours are the second-leading cause of cancer
deaths in the U.S. About 145,000 new lawsuits are diagnosed each
year and approximately 54,000 people decease from the disease. To
catch the malignant neoplastic disease early when it is more than treatable, the CDC
recommends yearly faecal blood screenings, clysters every 5 years,
or colonoscopies once a decade.

''Although this addition is encouraging, disparities persist
in colorectal malignant neoplastic disease diagnostic test use,'' the CDC said in its report. Factors contributing to some people not getting screened include
''lack of recommendation from a physician, deficiency of health
insurance and deficiency of a usual beginning of wellness care.''

Colon tumours caught early tin be treated by drugs including
Erbitux, made by New York-based Inc., and
Avastin, from Inc. of South San Francisco.

Whites got recommended diagnostic tests 63 percentage of the clip in 2006,
compared with 59 percentage for blacknesses and 56 percentage for Asians,
the CDC said. Fewer than one-half of Hispanics were screened.

Education also affected testing, with 69 percentage of people
with college grades getting screenings, compared with 57 percent
among those with lone high school diplomas.

To reach the newsman on this story:
in New House Of York at
.

EMERYVILLE, Calif., March 11 /PRNewswire-FirstCall/ -- Onyx
Pharmaceuticals, Inc. (Nasdaq: ) today announced that it will present
at the Cowen and Company 28th Annual Health Care Conference on Tuesday,
March 18, at 8:00 a.m. Eastern Time. Interested political parties may access a live
webcast of the presentation at: 83 It is recommended that hearers log on 15 proceedings early in order to
register and download any necessary software. For those not able to
participate during the unrecorded webcast, a recorded rematch of the presentation
will be available within 24 hours of the completion of the presentation
through April 18, 2008. Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to
improving the lives of people with malignant neoplastic disease by changing the manner malignant neoplastic disease is
treated(TM). The company, in coaction with Aspirin HealthCare
Pharmaceuticals, Inc., is developing and selling Nexavar(R), a small
molecule drug. Nexavar is currently approved for the treatment of advanced
kidney malignant neoplastic disease and liver cancer. Additionally, Nexavar is being investigated
in respective in progress trials in non-small cell lung cancer, melanoma, breast
cancer, and other cancers. For more than information about Onyx, visit the
company's website at . Nexavar(R) (sorafenib) tablets is a registered hallmark of Bayer
Pharmaceuticals Corporation.

Most colorectal malignant neoplastic disease is considered sporadic, meaning it happens in people with no household history of the disease. So, we can fault a batch of things on our family, but usually colorectal malignant neoplastic disease isn't one of them. It is more than likely to happen as people acquire older. In general, both work force and women at norm hazard of colorectal malignant neoplastic disease should get showing diagnostic tests at age 50.

Beginning at 50 old age of age, people at norm hazard for colorectal malignant neoplastic disease should be screened with faecal supernatural blood testing annually and or flexible flexible sigmoidoscopy every five years, colono scopy every 10 old age or double-contrast barium clyster every five to 10 years. Testing stool samples for familial changes that happen in colorectal malignant neoplastic disease cells may assist docs happen grounds of malignant neoplastic disease or precancerous polyps. In some patients, familial testing can steer showing and may be cost-effective. Genetic testing should be considered, especially in big households with many at-risk members; in such as situations, genotyping may be more than cost-effective than perennial endoscopy.

Approximately 25% of lawsuits are attributed to two types of colorectal cancers: familial and hereditary. Familial colorectal malignant neoplastic disease business relationships for about 20% of lawsuits and familial colorectal malignant neoplastic disease business relationships for the remaining five percent. You should discourse beginning earlier screening if you have got a personal history of colorectal malignant neoplastic disease or polyps, a strong household history of either, a personal history of chronic inflammatory intestine disease or a household history of a familial colorectal malignant neoplastic disease syndrome. Genetic guidance and familial testing for households who may have got a familial word form of colon cancer, such as as familial nonpolyposis colorectal malignant neoplastic disease (HNPCC) or familial adenomatous polyposis (FAP).

Since most colon polypuses and early malignant neoplastic diseases are soundless (produce no symptoms), it is of import to make showing and surveillance for colon malignant neoplastic disease in patients without symptoms or marks of the polypuses or cancers. Screening diagnostic tests are used to look for disease in people who make not have got any symptoms. Although there are good colorectal malignant neoplastic disease showing tests, not adequate people have got them done. The bulk of colorectal malignant neoplastic diseases would likely have got been avoided if the people had only undergone regular and appropriate screenings.

Cancer bar is action taken to take down the opportunity of getting cancer. Some malignant neoplastic disease bar trials are conducted with healthy people who have got got not had malignant neoplastic disease but who have an increased hazard for cancer.

Prevention of colorectal cancer: Although the exact cause of colorectal malignant neoplastic disease is not known, it is possible to forestall many colon malignant neoplastic diseases with the following:diet and exercise. It is of import to pull off the hazard factors you can control, such as as diet and exercise. Nevertheless, it looks that increasing the fibre content in the Western diet would be utile in the primary bar of colorectal cancer. You can begin today to develop children in malignant neoplastic disease bar habits, remembering that it's never too late to do healthy life style alterations for yourself as well.

Men aged 50 and over are at hazard for prostate gland gland jobs and possibly even prostate cancer. Checkup research have shown that there is a possibility that lipid-lowering medicine medications, normally used to take down cholesterol, may be helpful in cutting the hazard of getting advanced prostate gland malignant neoplastic disease in half. This includes the usage of drugs such as as as such as Lipitor, Mevacor, and Zocor. This research is based on 10 old age of information and is still in the early, observational stages. Preliminary determinations are that they will not assist with preventing or lowering the opportunity of getting early, curable prostate gland gland cancer.

How this was found

In 1990 there was a survey of 34,438 work force between the ages of 44 and 79 who did not have got prostate cancer. Over the adjacent old age they filled out wellness studies that included the usage of cholesterin lowering medications. In the twelvemonth 2000 ninety percentage of the work force in the survey said that they were taking lipid-lowering medicine drugs for their cholesterin and in the same twelvemonth 2,074 work force were confirmed as having prostate gland gland cancer.

The research worker compared the two groupings of work force in the study - the 1s taking lipid-lowering medicines and the 1s not taking it - and establish that the hazard of developing advanced prostate malignant neoplastic disease was cut in half, and the hazard of fatal malignant neoplastic disease was cut by a third. They also establish that the longer the patient took the lipid-lowering medicine medication, the less the hazard of malignant neoplastic disease became. They determined that there was a correlativity between prostate gland malignant neoplastic disease hazard factors and taking medical specialties such as as Lipitor.

The correlativity between malignant neoplastic disease cells and cholesterol

Medical research workers are now working on determining if lipid-lowering medicine medicines actually have some places that interfere with the malignant neoplastic disease or if simply lowering cholesterin degrees aid less the risk. Because cholesterin getas arterias and have got been establish in prostate gland malignant neoplastic disease cells, there is good indicant that the medical specialty plant on them as well, especially since it have already been establish to dispose of damaged cells through apoptosis, which is the procedure of the cells dying the normal programmed death.

Statins have also been shown to possess anti-inflammatory properties. Inflammation is a large job with many different malignant neoplastic diseases all over the body. Unfortunately the information on how lipid-lowering medicines work is still very informal and have not been reported in any medical diaries yet. The medical community is conducting intensive research before making many announcements.

How Atorvastatin works

Lipitor, a possible lipid-lowering medicine that could be used for prostate gland problems, take downs cholesterin by blocking the production of cholesterin in the body. It assists forestall bosom disease, hardening of the arteries, bosom attack, stroke, and vascular disease. It also take downs the hazard of all of these jobs in patients with coronary bosom disease and type 2 diabetes. Whether or not it will be utile in the treatment of prostate gland jobs stays to be seen. Always do certain you take medical specialties such as as Atorvastatin under the attention and advice of your primary doctor and never take it for statuses they have got not recommended the medicine for.

sfgate_get_fprefs();

(03-04) 13:21 Pacific Time SAN FRANCISCO --
The increased hazard of breast malignant neoplastic disease that come ups with taking oestrogen and progestogen internal secretions lingers even after women halt taking the pills, according to new research that rises more concerns for women who are despairing to ease the symptoms of menopause.

In the first follow-up survey of the landmark Women's Health Initiative, research workers establish that women who took the concerted oestrogen and progestogen therapy faced a greater menace of being diagnosed with not just breast malignant neoplastic disease but all types of malignant neoplastic disease up to three old age after they halt taking hormones.

The survey results, released in the Diary of the American Checkup Association today, are distressing for women and docs who had hoped that the hazards associated with internal secretion substitution therapy faded once women stopped taking the drugs.

"I don't believe this news should be awful to women," said Dr. Marcia Stefanick, a professor of medical specialty at the Leland Stanford Prevention Research Center and a senior writer of the study. "But I personally believe that women should only travel on menopausal internal secretion therapy if they have got terrible symptoms. They should really believe about whether they're so bad off that they desire to begin something that come ups with all these risks."

The new research reenforces what docs have got suggested for years: that women who must take internal secretions take the least dose possible and that they halt taking the drugs as soon as they are able. Stefanick and other research workers state that based on the Women's Health Enterprise results, five old age is clearly too long to take the drugs, but the hazards could be greatly reduced if women took internal secretions for just two or three years.

Two types of internal secretion therapy are available: estrogen-only and concerted oestrogen and progestin. The new research uses only to women on concerted internal secretion therapy. Women take internal secretions during and after climacteric to relieve uncomfortable symptoms such as as hot flashes, temper swings and nighttime sweats. Hopes for therapy fade

Roughly 25 million women in the United States take some word form of internal secretion therapy, usually the concerted oestrogen and progestin.

Doctors once believed that internal secretion therapy had respective long-term wellness benefits, including improved bosom health. But the Women's Health Initiative, which was developed to detect the hazards and benefits of internal secretion therapy, was halted in 2002 when women on concerted therapy showed an increased hazard of bosom disease, shot and breast cancer.

Soon many one thousands of women stopped taking hormones. The bosom disease hazard later was establish to be negligible in little women who started treatment at the oncoming of menopause, and the increased hazard of shot was establish to be minimal. Hormone substitution therapy makes clasp benefits, including less rates of colon malignant neoplastic disease and os fractures.

In the up-to-the-minute research, docs establish that the hazard of shot and bosom onslaught dissipated soon after women stopped taking the drugs. But the benefits of internal secretion therapy also faded. And the hazard of malignant neoplastic disease remained.

"We don't desire to overplay this thing. There really are a relatively little figure of negative events. But it acquires you rethinking this treatment. It changes the risk-benefit ratio," said Dr. Rowan Chlebowski, an research worker with the Los Angeles Biomedical Research Institute and an writer of the study.

The Women's Health Enterprise involved 16,608 participants who were taking concerted internal secretion therapy or a placebo for an norm of 5.6 years. Of the original participants, 15,730 were involved in the follow-up research for an norm of 2.4 old age after the trial ended.

While on the hormones, women had a 26 percentage higher hazard for breast malignant neoplastic disease than participants taking placebos. Two to three old age after fillet the drugs, the hazard of developing breast malignant neoplastic disease was 27 percentage higher for those women than for participants taking placebos. Estrogen's influence

Women on internal secretion therapy also had a 24 percentage greater hazard of developing any type of malignant neoplastic disease after they stopped the drugs.

That's an interesting consequence from a research standpoint, docs said, because it demoes that oestrogen might play a larger function than previously thought in eating all sorts of cancers.

"Estrogen clearly drives breast cancer, but there was A small more than lung cancer, too, and that's a spot of a surprise," Stefanick said. "The fact that you have got got another malignant neoplastic disease here, another 1 there, it really raises the inquiry of estrogen's possible influence on a broad scope of cancer."

Researchers from Wyeth, the pharmaceutical company that brands the internal secretions used in the Women's Health Enterprise study, said the new research doesn't change what women have been told for some clip now - that internal secretions are good to women who necessitate alleviation from menopause, and that they should be taken in low doses for as short a clip as possible.

They added that the research doesn't separate the hazard to women of different age groups, which was a job with the original study. Researchers eventually discovered that the bosom disease hazard was only a job with women in their 60s and aged pickings internal secretions - that's of import because women in their 50s are more than likely to take hormones.

"The hazards really make alteration for the 50- to 59-year-old woman, for the newly menopausal woman, and that is usually the adult female seeking relief," said Dr. Eileen Helzner, caput of medical attention for Wyeth's women's wellness attention division. "These current determinations make not impact the counsel for the appropriate usage of internal secretion therapy. We still strongly promote women to talk with their ain doctors and do determinations on their individual hazards and benefits."

Hormone therapy risks, benefits

Research from the Women's Health Enterprise have revealed a amalgamated bag of hazards and benefits from internal secretion therapy since the survey was halted in 2002. Among the determinations were that, when compared to a placebo group, women on concerted internal secretion therapy had:

-- Higher hazard for breast cancer, shot and blood coagulums while taking the drugs.

-- Higher menace of bosom onslaught for women aged than 60 while taking the drugs.

-- Lower Berth rates of colon malignant neoplastic disease and os breaks while on the drugs.

-- Higher hazard for breast malignant neoplastic disease and other types of malignant neoplastic disease up to three old age after fillet the drugs.

In addition, research have establish that:

-- The benefits of internal secretion therapy faded after women stopped the drugs, along with the hazards of stroke, blood coagulums and bosom attack.

-- The tools used to diagnose breast malignant neoplastic disease - namely mammograms and breast biopsy - are less effectual in women who are taking concerted internal secretion therapy.

E-mail Erin Allday at .